Danielle Brill
Stock Analyst at Raymond James
(1.20)
# 3,342
Out of 4,814 analysts
75
Total ratings
31.25%
Success rate
-12.95%
Average return
Main Sectors:
Stocks Rated by Danielle Brill
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QURE uniQure | Upgrades: Strong Buy | $20 → $52 | $13.00 | +300.00% | 6 | Dec 10, 2024 | |
| TECX Tectonic Therapeutic | Initiates: Outperform | $65 | $16.96 | +283.25% | 1 | Nov 20, 2024 | |
| DNLI Denali Therapeutics | Reinstates: Market Perform | n/a | $12.72 | - | 1 | Oct 10, 2024 | |
| BMRN BioMarin Pharmaceutical | Reinstates: Outperform | $79 | $59.12 | +33.63% | 1 | Oct 10, 2024 | |
| RGNX REGENXBIO | Reinstates: Outperform | $18 | $5.96 | +202.01% | 1 | Oct 10, 2024 | |
| NBIX Neurocrine Biosciences | Reinstates: Outperform | $155 | $100.10 | +54.85% | 5 | Oct 10, 2024 | |
| IMVT Immunovant | Reinstates: Outperform | $36 | $15.15 | +137.70% | 4 | Oct 10, 2024 | |
| HRMY Harmony Biosciences Holdings | Reinstates: Outperform | $40 | $27.94 | +43.16% | 7 | Oct 10, 2024 | |
| SRPT Sarepta Therapeutics | Reinstates: Outperform | $150 | $53.79 | +178.86% | 3 | Oct 10, 2024 | |
| BIIB Biogen | Reinstates: Market Perform | n/a | $118.61 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $7.44 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $489.10 | - | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Strong Buy | $605 | $593.60 | +1.92% | 7 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Market Perform | n/a | $14.71 | - | 5 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $50 | $35.16 | +42.23% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Outperform | $51 | $27.66 | +84.38% | 2 | Oct 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $43 | $42.24 | +1.80% | 5 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $5 | $0.31 | +1,492.36% | 5 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $47.45 | - | 9 | Sep 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.29 | - | 5 | Jun 27, 2023 |
uniQure
Dec 10, 2024
Upgrades: Strong Buy
Price Target: $20 → $52
Current: $13.00
Upside: +300.00%
Tectonic Therapeutic
Nov 20, 2024
Initiates: Outperform
Price Target: $65
Current: $16.96
Upside: +283.25%
Denali Therapeutics
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $12.72
Upside: -
BioMarin Pharmaceutical
Oct 10, 2024
Reinstates: Outperform
Price Target: $79
Current: $59.12
Upside: +33.63%
REGENXBIO
Oct 10, 2024
Reinstates: Outperform
Price Target: $18
Current: $5.96
Upside: +202.01%
Neurocrine Biosciences
Oct 10, 2024
Reinstates: Outperform
Price Target: $155
Current: $100.10
Upside: +54.85%
Immunovant
Oct 10, 2024
Reinstates: Outperform
Price Target: $36
Current: $15.15
Upside: +137.70%
Harmony Biosciences Holdings
Oct 10, 2024
Reinstates: Outperform
Price Target: $40
Current: $27.94
Upside: +43.16%
Sarepta Therapeutics
Oct 10, 2024
Reinstates: Outperform
Price Target: $150
Current: $53.79
Upside: +178.86%
Biogen
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $118.61
Upside: -
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $7.44
Upside: -
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $489.10
Upside: -
Oct 10, 2024
Reinstates: Strong Buy
Price Target: $605
Current: $593.60
Upside: +1.92%
Oct 10, 2024
Reinstates: Market Perform
Price Target: n/a
Current: $14.71
Upside: -
Oct 10, 2024
Reinstates: Outperform
Price Target: $50
Current: $35.16
Upside: +42.23%
Oct 10, 2024
Reinstates: Outperform
Price Target: $51
Current: $27.66
Upside: +84.38%
May 10, 2024
Maintains: Outperform
Price Target: $40 → $43
Current: $42.24
Upside: +1.80%
Nov 14, 2023
Maintains: Outperform
Price Target: $9 → $5
Current: $0.31
Upside: +1,492.36%
Sep 18, 2023
Downgrades: Underperform
Price Target: n/a
Current: $47.45
Upside: -
Jun 27, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $0.29
Upside: -